114450.KQ KPX Lifescience.Co.Ltd
- Market cap
- KRW 39.8B
- P/E
- -
- P/B
- 0.89x
- ROE
- 27.4%
- Dividend yield
- -
- Fundamental score
- 2.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 114450.KQ undervalued?
Graham numberThe Graham number of KPX Lifescience.Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
KPX Lifescience.Co.Ltd fundamental analysis
10 of 22 checks passedROE 2/2
High return on equity (27.4%), above 20%.
ROA 1/1
Return on assets (20.7%) is above the industry median (3.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-93.2%) is below the industry median (6.6%).
Revenue Growth 1/2
Revenue grew 3.4% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (3.3%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Debt Coverage 1/1
Operating cash flow covers 20% of total debt.
Interest Coverage 1/1
EBIT is 28.2x against interest expense, well covered.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (0.9x) is above the industry median (0.8x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
KPX Lifescience.Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an…
Full company profileKPX Lifescience.Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
KPX Lifescience.Co.Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 43.3B | 42.6B | 32.8B | 37.6B | 24.6B | 25.3B | 36.5B | 22.4B | 24.9B | 40.3B | 69.2B |
| Gross Profit | 7.39B | 4.65B | 70.8M | 3.03B | -74.6M | -2.27B | -1.36B | -2.31B | 2.98B | 2.47B | 7.13B |
| Operating Income | 5.03B | 2.41B | -1.95B | 591M | -1.91B | -4.65B | -3.96B | -16.7B | 377M | 204M | 4.78B |
| EBITDA | - | - | - | - | - | - | 21.9M | -13.6B | 2.57B | 1.14B | 13.4B |
| Net Income | 4.50B | 2.22B | -1.45B | 1.20B | -1.06B | -3.14B | -3.53B | -16.4B | 1.56B | 110M | 12.3B |
| EPS | 300 | 148 | -96 | 80 | -71 | -157 | -176 | -821 | 82 | 5.55 | 619 |
| Balance Sheet | |||||||||||
| Total Assets | 77.1B | 73.0B | 69.4B | 71.9B | 70.8B | 72.0B | 62.4B | 43.8B | 45.0B | 54.9B | 59.4B |
| Total Liabilities | 15.4B | 10.9B | 10.3B | 11.5B | 11.5B | 15.7B | 9.79B | 7.87B | 9.22B | 16.6B | 14.5B |
| Shareholders' Equity | 61.7B | 62.1B | 59.1B | 60.4B | 59.4B | 56.3B | 52.6B | 36.0B | 35.7B | 38.3B | 44.9B |
| Cash & Short-term Investments | 26.3B | 23.7B | 20.2B | 20.0B | 14.8B | 15.9B | 16.6B | 14.5B | 12.9B | 13.4B | 14.2B |
| Total Debt | - | - | - | - | 6.24B | - | - | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 7.07B | 5.68B | 5.38B | 4.24B | 1.90B | 611M | -4.55B | 370M | 525M | 364M | 1.49B |
| Capital Expenditure | 1.60B | 4.31B | 7.49B | 3.60B | 2.67B | 3.44B | 1.48B | 475M | 463M | 1.16B | 1.98B |
| Free Cash Flow | - | - | - | -943M | -765M | -2.83B | -6.03B | -105M | 62.8M | -796M | -497M |
| Ratios | |||||||||||
| ROE | 7.3% | 3.6% | -2.4% | 2.0% | -1.8% | -5.6% | -6.7% | -45.5% | 4.4% | 0.3% | 27.4% |
| ROA | 5.8% | 3.0% | -2.1% | 1.7% | -1.5% | -4.4% | -5.6% | -37.3% | 3.5% | 0.2% | 20.7% |
| Net Profit Margin | 10.4% | 5.2% | -4.4% | 3.2% | -4.3% | -12.4% | -9.7% | -73.1% | 6.3% | 0.3% | 17.7% |
| Debt to Equity | - | - | - | - | 0.11x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
KPX Lifescience.Co.Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | KRW 1.50B | 100 | - |
| 2017 | KRW 2.01B | 134 | 90.4% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:3 on Sep 5, 2023.
Who owns KPX Lifescience.Co.Ltd
- Insiders 25.00%
- Institutions 0.00%
- Public & others 75.00%
- Shares outstanding 15.0M
- Free float 11.1M
KPX Lifescience.Co.Ltd company profile
- Company name
- KPX Lifescience.Co.Ltd
- Ticker
- 114450.KQ
- ISIN
- KR7114450000
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 84, Yeosusandan 2-ro, Yeosu-Si, South Korea
- Phone
- 82 6 1681 4600
- Website
- kpxls.com
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an antidepressant raw material; and AM19, an antibiotic intermediate. The company was formerly known as MNH Laboratories Co., Ltd. and changed its name to KPX Lifescience.Co.,Ltd. in September 2008. The company was founded in 2005 and is headquartered in Yeosu, South Korea. KPX Lifescience.Co.,Ltd. is a subsidiary of KPX Holdings Co., Ltd.
KPX Lifescience.Co.Ltd management
2- Jun-Yeong YangChief Exec. Officer · born 1969
- Ui-Nam GwakChief Exec. Officer · born 1953